Review question | In people with chronic plaque psoriasis at high impact or difficult-to-treat sites (scalp, flexures, face), what are the clinical effectiveness, safety, tolerability and cost effectiveness of vitamin D or vitamin D analogues, mild to very potent corticosteroids, combined or concurrent vitamin D or vitamin D analogue and potent corticosteroid, pimecrolimus, tacrolimus, tar, dithranol and retinoids compared with placebo, corticosteroids or vitamin D or vitamin D analogues? |
Objectives | The aims of this review are to assess the clinical and cost-effectiveness and safety of available topical therapies for chronic plaque psoriasis at high impact or difficult-to-treat sites (scalp, flexures, face); and to establish the period of time that topical therapies should be administered for at these sites before efficacy is reviewed and the patient is moved on to alternative therapy if topicals are ineffective. |
Population | All people with chronic plaque psoriasis at high impact or difficult-to-treat sites (scalp, flexures, face) |
Subgroups | The following groups will be considered separately if data are available:
Children Different psoriasis phenotypes – e.g., pustular, erythrodermic, plaque, guttate, flexural or sebopsoriasis The following factors will be considered for subgroup analysis if heterogeneity is present:
|
Intervention |
Vitamin D or vitamin D analogues (calcipotriol/calcipotriene [Dovonex], calcitriol [Silkis], tacalcitol [Curatoderm]) Mild to very potent corticosteroids (hydrocortisone [Dioderm, Mildison, Synalar], clobetasone butyrate [Eumovate], fludroxycortide [Haelan], alclometasone dipropionate [Modrasone], fluocortolone [Ultralanum Plain], betamethasone dipropionate [Betnovate-RD], betamethasone valerate [Betacap, Betesil, Bettamousse, Betnovate, Cutivate, Diprosone, Elocon], budesonide, fluticasone propionate [Cutivate], mometasone furoate [Elocon], fluocinolone acetonide [Synalar], beclomethasone dipropionate, triamcinolone acetonide, hydrocortisone butyrate [Locoid, Locoid Crelo, Metosyn, Nerisone, Synalar], clobetasol propionate [Clarelux, Dermovate, Etrivex], diflucortolone valerate [Nerisone]) Combined [combined product containing calcipotriol monohydrate and betamethasone dipropionate, Xamiol] or concurrent vitamin D or vitamin D analogue and potent corticosteroid (one applied in the morning and one in the evening) Pimecrolimus [Elidel] Tacrolimus [Protopic] Tar [Carbo-Dome, Cocois, Exorex, Psoriderm, Sebco, Coal Tar Solution, BP Pinetarsol, Polytar, Emollient, Psoriderm] Dithranol [Dithrocream, Micanol, Psorin] Retinoids (tazarotene [Zorac])
|
Comparison |
|
Outcomes |
Clear/nearly clear or marked improvement (at least 75% improvement on Investigator’s assessment of overall global improvement (IAGI) or clear/nearly clear/minimal (not mild) on Physician’s Global Assessment (PGA)) Clear/nearly clear or marked improvement (at least 75% improvement on Patient’s assessment of overall global improvement (PAGI) or clear/nearly clear/minimal (not mild) on Patient’s Global Assessment) Percentage change in PASI Change in DLQI Duration of remission Time-to-remission or time-to-maximum effect Withdrawal due to toxicity Withdrawal due to lack of efficacy Skin atrophy
|
Study design | RCTs or systematic reviews |
Population size and directness |
Sample size greater than 25 per arm Efficacy data to be reported for the primary end point of the trial if multiple time points are reported No restrictions on treatment duration Studies with indirect populations will not be considered Studies only comparing different dosages or formulations of the same intervention will not be included Studies comparing interventions within the classes of either vitamin D or vitamin D analogues or corticosteroids will not be included (unless the comparison is for frequency of administration e.g., once or twice daily dosing) Studies assessing the whole body (including scalp, flexures and face), that do not stratify results by site of involvement will be included in this review.
|
Setting |
|
Search Strategy | See appendix D |
Review Strategy | Appraisal of methodological quality
Synthesis of data
Meta-analysis will be conducted where appropriate Data on all vitamin D or vitamin D analogues will be pooled into one analysis as will data on any potent corticosteroids and on very potent corticosteroids The following information will also be recorded:
|